|Mr. Stephen R. Davis||CEO & Director||1.23M||5.28M||1961|
|Dr. Srdjan R. Stankovic||Pres||1.12M||7.82M||1957|
|Ms. Elena H. Ridloff C.F.A., CFA||Exec. VP & CFO||646.54k||256.2k||1980|
|Mr. Austin D. Kim||Exec. VP, Gen. Counsel & Sec.||626.76k||240.8k||1964|
|Mr. James K. Kihara||VP, Corp. Controller & Principal Accounting Officer||N/A||N/A||1980|
|Mr. Bob Mischler||Sr. VP of Strategy & Technology Operations||N/A||N/A||N/A|
|Mr. Mark C. Johnson||VP of Investor Relations||N/A||N/A||N/A|
|Ms. Stephanie Fagan||Sr. VP of Corp. Affairs & Chief Communications Officer||N/A||N/A||N/A|
|Ms. Charmaine Lykins||Sr. VP of Global Product Planning & Chief Marketing Officer||N/A||N/A||N/A|
|Dr. Mary Ellen Turner||Sr. VP of Pharmacovigilance & Corp. Safety Officer||N/A||N/A||N/A|
ACADIA Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of small molecule drugs that address unmet medical needs in central nervous system disorders. The company offers NUPLAZID (pimavanserin) for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis; Trofinetide, a novel synthetic analog for the treatment of Rett syndrome; ACP-044, a novel first-in-class orally administered non-opioid analgesic for treating acute and chronic pain; and ACP-319, a positive allosteric modulator of the muscarinic receptor for treating cognition and schizophrenia. It is also developing pimavanserin as a treatment for dementia-related psychosis and as an adjunctive treatment for schizophrenia; and pimavanserin as an adjunctive treatment for major depressive disorder. ACADIA Pharmaceuticals Inc. was founded in 1993 and is headquartered in San Diego, California.
ACADIA Pharmaceuticals Inc.’s ISS Governance QualityScore as of June 1, 2021 is 6. The pillar scores are Audit: 6; Board: 4; Shareholder Rights: 8; Compensation: 6.